21018 Pharmaceutical “Global Thalassemia” Market: Industry Analysis & Outlook (2017-2021)
Press
Release - 09 April 2018
Global
Research and Development News
--
.
.
Report
Description-
'
'
Thalassemia is a blood disorder that causes
abnormal production of hemoglobin in an affected person. It is a
genetic disorder inherited from parents. Hemoglobin carries oxygen in
the blood and is produced by two proteins called alpha globin and
beta globin. A person inherits four genes to produce alpha globin
protein and two genes to produce alpha globin protein from parents.
Thalassemia is caused by any abnormality or mutation in one or more
genes responsible for hemoglobin production.
When a person inherits only one affected
gene from parents then the person becomes a carrier of thalassemia.
Since, thalassemia is an inherited disorder; one of the parents must
be a carrier for thalassemia. When both the parents are carriers then
the risk of giving birth to a thalassemia affected child is quite
high. Thalassemia is generally of two types: alpha thalassemia and
beta thalassemia.
'
'
Globally, thalassemia affects approximately
7% of the population and many of them are transfusion dependent
patients. The global thalassemia market is likely to be driven with
the growing market of bone marrow transplant and blood transfusion
therapy, supported by high numbers of transfusion dependent patients.
The U.S. is expected to be the first region to
start selling of thalassemia drugs due to developing drug pipeline
and later on, market penetration of thalassemia drugs would occur in
Europe. U.S. and Europe have high prevalence of severe forms of
beta-thalassemia which would result into a high demand for
thalassemia drugs in future.
The global thalassemia market is expected to grow
in future with mounting prevalence of thalassemia, rising Asian
population, increasing healthcare expenditure, rising spending on
pharmaceuticals R&D and stem cell therapy research. Key trends of
this market include progressing drug pipeline, rising scope for gene
therapy and growing awareness towards thalassemia. However, there are
some factors which can hinder growth of the market including
regulatory changes, associated risks and high cost of treatment.
The report “Global Thalassemia Market: Industry
Analysis & Outlook (2017-2021)” by Koncept Analytics provides
an extensive research and detailed analysis of the present market
along with future outlook. The report discusses the major growth
drivers and challenges of the market, covering U.S, and Europe along
with the global market. The report profiles key players of the market
including GlaxoSmithKline Plc, Celgene, Bluebird Bio and Bellicum
Pharmaceuticals.
– More
Clear Details get Table of Contents
https://www.researchmoz.us/global-thalassemia-market-industry-analysis-outlook-20172021-report.html/toc
'
'
1. Introduction
1.1 Thalassemia
1.2 Types of Thalassemia
1.3 Diagnosis and Treatment
1.1 Thalassemia
1.2 Types of Thalassemia
1.3 Diagnosis and Treatment
2. Global Thalassemia Market
2.1 Thalassemia Population by Category
2.2 Thalassemia Market by Treatment
2.2.1 Global Bone Marrow Market Forecast by Value
2.2.2 Global Luspatercept Revenue Forecast for Beta-Thalassemia
2.1 Thalassemia Population by Category
2.2 Thalassemia Market by Treatment
2.2.1 Global Bone Marrow Market Forecast by Value
2.2.2 Global Luspatercept Revenue Forecast for Beta-Thalassemia
3. Regional Market Analysis
3.1 The U.S.
3.1.1 The U.S. Beta-Thalassemia Patient Volume Forecast
3.1.2 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume Forecast
3.1.3 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume by Category
3.1.4 The U.S. Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
3.1.5 The U.S. Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
3.1.6 The U.S. Luspatercept Drug Revenue Forecast for Beta-Thalassemia
3.2 Europe
3.2.1 Europe Beta-Thalassemia Patient Volume Forecast
3.2.2 Europe Beta-Thalassemia Intermedia/Major Patient Volume Forecast
3.2.3 Europe Beta-Thalassemia Intermedia/Major Patient Volume by Category
3.2.4 Europe Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
3.2.5 Europe Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
3.2.6 Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia
3.1 The U.S.
3.1.1 The U.S. Beta-Thalassemia Patient Volume Forecast
3.1.2 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume Forecast
3.1.3 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume by Category
3.1.4 The U.S. Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
3.1.5 The U.S. Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
3.1.6 The U.S. Luspatercept Drug Revenue Forecast for Beta-Thalassemia
3.2 Europe
3.2.1 Europe Beta-Thalassemia Patient Volume Forecast
3.2.2 Europe Beta-Thalassemia Intermedia/Major Patient Volume Forecast
3.2.3 Europe Beta-Thalassemia Intermedia/Major Patient Volume by Category
3.2.4 Europe Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
3.2.5 Europe Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
3.2.6 Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Mounting Prevalence of Thalassemia
4.1.2 Increasing Pharmaceutical R&D Spending
4.1.3 Increasing Spending on Stem Cell Research
4.1.4 Rising Healthcare Expenditure
4.1.5 Rising Asian Population
4.2 Key Trends & Developments
4.2.1 Progressing Drugs under Pipeline
4.2.2 Rising Scope for Gene Therapy
4.2.3 Increasing Awareness towards Thalassemia
4.3 Key Challenges
4.3.1 Regulatory Challenges
4.3.2 Other Associated Risks
4.3.3 Highly Expensive Treatment
4.1 Growth Drivers
4.1.1 Mounting Prevalence of Thalassemia
4.1.2 Increasing Pharmaceutical R&D Spending
4.1.3 Increasing Spending on Stem Cell Research
4.1.4 Rising Healthcare Expenditure
4.1.5 Rising Asian Population
4.2 Key Trends & Developments
4.2.1 Progressing Drugs under Pipeline
4.2.2 Rising Scope for Gene Therapy
4.2.3 Increasing Awareness towards Thalassemia
4.3 Key Challenges
4.3.1 Regulatory Challenges
4.3.2 Other Associated Risks
4.3.3 Highly Expensive Treatment
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 Market Cap Comparison of Key Players
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 Market Cap Comparison of Key Players
6. Company Profiles
6.1 GlaxoSmithKline Plc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Celgene
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Bluebird Bio
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Bellicum Pharmaceuticals
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
6.1 GlaxoSmithKline Plc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Celgene
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Bluebird Bio
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Bellicum Pharmaceuticals
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
List of Table
Drugs under Development for Thalassemia
(2016)
Bluebird Bio’s Product Pipeline
Bluebird Bio’s Product Pipeline
List of Chart
Types of Thalassemia
Global Thalassemia Population by Category (2016)
Global Bone Marrow Market Forecast by Value (2016-2021)
Global Luspatercept Revenue Forecast for Beta-Thalassemia (2019-2025)
The U.S. Beta-Thalassemia Patient Volume Forecast (2016-2021)
The U.S. Beta-Thalassemia Intermedia/Major Patient Volume Forecast (2016-2021)
The U.S. Beta-Thalassemia Intermedia/Major Patient Volume by Category (2016)
The U.S. Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast (2016-2021)
The U.S. Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast (2016-2021)
The U.S. Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2019-2025)
Europe Beta-Thalassemia Patient Volume Forecast (2016-2021)
Europe Beta-Thalassemia Intermedia/Major Patient Volume Forecast (2016-2021)
Europe Beta-Thalassemia Intermedia/Major Patient Volume by Category (2016)
Europe Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast (2016-2021)
Europe Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast (2016-2021)
Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2020-2025)
Global Pharmaceutical R&D Spending (2013-2016)
NIH Spending on Stem Cell Research (2013-2016)
Global Healthcare Expenditure per Capita (2012-2016)
East Asia-Pacific Population (2012-2016)
Global Thalassemia Key Players - Revenue Comparison (2016)
Global Thalassemia Key Players - Market Cap Comparison (2016)
Global Thalassemia Population by Category (2016)
Global Bone Marrow Market Forecast by Value (2016-2021)
Global Luspatercept Revenue Forecast for Beta-Thalassemia (2019-2025)
The U.S. Beta-Thalassemia Patient Volume Forecast (2016-2021)
The U.S. Beta-Thalassemia Intermedia/Major Patient Volume Forecast (2016-2021)
The U.S. Beta-Thalassemia Intermedia/Major Patient Volume by Category (2016)
The U.S. Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast (2016-2021)
The U.S. Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast (2016-2021)
The U.S. Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2019-2025)
Europe Beta-Thalassemia Patient Volume Forecast (2016-2021)
Europe Beta-Thalassemia Intermedia/Major Patient Volume Forecast (2016-2021)
Europe Beta-Thalassemia Intermedia/Major Patient Volume by Category (2016)
Europe Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast (2016-2021)
Europe Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast (2016-2021)
Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2020-2025)
Global Pharmaceutical R&D Spending (2013-2016)
NIH Spending on Stem Cell Research (2013-2016)
Global Healthcare Expenditure per Capita (2012-2016)
East Asia-Pacific Population (2012-2016)
Global Thalassemia Key Players - Revenue Comparison (2016)
Global Thalassemia Key Players - Market Cap Comparison (2016)
Comments
Post a Comment